XOMA (NASDAQ:XOMA) Rating Increased to Buy at Wall Street Zen

XOMA (NASDAQ:XOMA) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages have also recently weighed in on XOMA. Benchmark began coverage on shares of XOMA in a research note on Thursday, April 17th. They set a “buy” rating and a $35.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $104.00 target price on shares of XOMA in a report on Wednesday, May 28th.

XOMA Stock Down 3.0%

Shares of NASDAQ XOMA opened at $23.85 on Friday. The business has a 50-day moving average price of $23.91 and a 200 day moving average price of $24.70. The stock has a market cap of $285.41 million, a PE ratio of -6.85 and a beta of 0.94. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 52-week low of $18.35 and a 52-week high of $35.00.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.32. The business had revenue of $15.91 million during the quarter, compared to the consensus estimate of $6.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. Equities research analysts forecast that XOMA will post -1.41 earnings per share for the current year.

Insider Activity

In related news, CEO Owen Hughes sold 25,637 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total transaction of $650,667.06. Following the completion of the transaction, the chief executive officer now directly owns 62,701 shares of the company’s stock, valued at $1,591,351.38. This represents a 29.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CIO Bradley Sitko purchased 4,134 shares of the business’s stock in a transaction that occurred on Friday, March 21st. The shares were purchased at an average cost of $23.89 per share, with a total value of $98,761.26. Following the completion of the acquisition, the executive now directly owns 10,484 shares of the company’s stock, valued at $250,462.76. This represents a 65.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 29,312 shares of company stock valued at $735,061. Insiders own 9.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Woodline Partners LP raised its holdings in XOMA by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock worth $3,359,000 after purchasing an additional 12,284 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in XOMA by 3.3% during the first quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company’s stock worth $2,587,000 after purchasing an additional 4,113 shares in the last quarter. Nuveen LLC purchased a new position in XOMA during the first quarter worth about $286,000. Deutsche Bank AG raised its holdings in XOMA by 5,087.9% during the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 6,309 shares in the last quarter. Finally, CM Management LLC raised its holdings in XOMA by 16.4% during the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock worth $1,276,000 after purchasing an additional 9,000 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.